Literature DB >> 7743758

Topical treatment of diabetic foot ulcers: an economic analysis of treatment alternatives and strategies.

J Apelqvist1, G Ragnarson-Tennvall, J Larsson.   

Abstract

In a prospective study, 314 patients with diabetic foot ulcers were followed and 40 patients died before healing occurred. In those patients who healed, a retrospective economic analysis of the costs for topical treatment was performed. The aim of the study was to analyse the costs and discuss how different treatment strategies influence total costs. Data collected for each patient were total time to healing, treatment time for each type of dressing, and the frequency of dressing changes. Material costs for the dressings, labour, and travelling costs were calculated separately. A formula for simulation of economic consequences of different treatment strategies including the introduction of new strategies was designed. The cost for topical treatment was strongly related to the severity of the ulcer and wound healing time. The average weekly cost per patient for topical treatment varied between 40.3 pounds and 385 pounds. The dominating costs for topical treatment were expenses for staff and transportation. The most important factor to reduce costs is the frequency of dressing changes. The study emphasizes the need for prospective comparative studies of cost effectiveness in topical treatment strategies.

Entities:  

Mesh:

Year:  1995        PMID: 7743758     DOI: 10.1111/j.1464-5491.1995.tb00442.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

Review 1.  Cost-effective management of diabetic foot ulcers. A review.

Authors:  G Ragnarson-Tennvall; J Apelqvist
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

Review 2.  The use of gauze: will it ever change?

Authors:  Vanessa J Jones
Journal:  Int Wound J       Date:  2006-06       Impact factor: 3.315

3.  Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection.

Authors:  F de Lalla; G Pellizzer; M Strazzabosco; Z Martini; G Du Jardin; L Lora; P Fabris; P Benedetti; G Erle
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Costs of deep foot infections in patients with diabetes mellitus.

Authors:  G R Tennvall; J Apelqvist; M Eneroth
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

5.  Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.

Authors:  O Ghatnekar; U Persson; M Willis; K Odegaard
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.

Authors:  Astrid Langer; Wolf Rogowski
Journal:  BMC Health Serv Res       Date:  2009-07-10       Impact factor: 2.655

Review 7.  Optimising antimicrobial therapy in diabetic foot infections.

Authors:  Nalini Rao; Benjamin A Lipsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.